In contrast, poor metabolizers exhibit a decrease in the safety of ASMs; for example, CYP2C9*3/*3 carriers show high plasma levels of PHT [27] and valproic acid which can induce ADRs [33]. Here, CYP2C9 is linked to pulmonary hypertension, primary, 1.